195 related articles for article (PubMed ID: 20501622)
1. A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer.
Armstrong AJ; Netto GJ; Rudek MA; Halabi S; Wood DP; Creel PA; Mundy K; Davis SL; Wang T; Albadine R; Schultz L; Partin AW; Jimeno A; Fedor H; Febbo PG; George DJ; Gurganus R; De Marzo AM; Carducci MA
Clin Cancer Res; 2010 Jun; 16(11):3057-66. PubMed ID: 20501622
[TBL] [Abstract][Full Text] [Related]
2. Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine.
Perotti A; Locatelli A; Sessa C; Hess D; Viganò L; Capri G; Maur M; Cerny T; Cresta S; Rojo F; Albanell J; Marsoni S; Corradino I; Berk L; Rivera VM; Haluska F; Gianni L
J Clin Oncol; 2010 Oct; 28(30):4554-61. PubMed ID: 20855840
[TBL] [Abstract][Full Text] [Related]
3. Ribosomal S6 kinase and AKT phosphorylation as pharmacodynamic biomarkers in patients with myelodysplastic syndrome treated with RAD001.
Advani AS; Mahfouz RZ; Maciejewski J; Rybicki L; Sekeres M; Tripp B; Kalaycio M; Bates J; Saunthararajah Y
Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):172-177.e1. PubMed ID: 24332215
[TBL] [Abstract][Full Text] [Related]
4. Rapamycin has paradoxical effects on S6 phosphorylation in rats with and without seizures.
Chen L; Hu L; Dong JY; Ye Q; Hua N; Wong M; Zeng LH
Epilepsia; 2012 Nov; 53(11):2026-33. PubMed ID: 23145776
[TBL] [Abstract][Full Text] [Related]
5. Single-cell pharmacodynamic monitoring of S6 ribosomal protein phosphorylation in AML blasts during a clinical trial combining the mTOR inhibitor sirolimus and intensive chemotherapy.
Perl AE; Kasner MT; Shank D; Luger SM; Carroll M
Clin Cancer Res; 2012 Mar; 18(6):1716-25. PubMed ID: 22167413
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma.
Cloughesy TF; Yoshimoto K; Nghiemphu P; Brown K; Dang J; Zhu S; Hsueh T; Chen Y; Wang W; Youngkin D; Liau L; Martin N; Becker D; Bergsneider M; Lai A; Green R; Oglesby T; Koleto M; Trent J; Horvath S; Mischel PS; Mellinghoff IK; Sawyers CL
PLoS Med; 2008 Jan; 5(1):e8. PubMed ID: 18215105
[TBL] [Abstract][Full Text] [Related]
7. Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation.
Ghosh PM; Malik SN; Bedolla RG; Wang Y; Mikhailova M; Prihoda TJ; Troyer DA; Kreisberg JI
Endocr Relat Cancer; 2005 Mar; 12(1):119-34. PubMed ID: 15788644
[TBL] [Abstract][Full Text] [Related]
8. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways.
Han S; Khuri FR; Roman J
Cancer Res; 2006 Jan; 66(1):315-23. PubMed ID: 16397245
[TBL] [Abstract][Full Text] [Related]
9. LY303511 (2-piperazinyl-8-phenyl-4H-1-benzopyran-4-one) acts via phosphatidylinositol 3-kinase-independent pathways to inhibit cell proliferation via mammalian target of rapamycin (mTOR)- and non-mTOR-dependent mechanisms.
Kristof AS; Pacheco-Rodriguez G; Schremmer B; Moss J
J Pharmacol Exp Ther; 2005 Sep; 314(3):1134-43. PubMed ID: 15923340
[TBL] [Abstract][Full Text] [Related]
10. The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study.
Macaskill EJ; Bartlett JM; Sabine VS; Faratian D; Renshaw L; White S; Campbell FM; Young O; Williams L; Thomas JS; Barber MD; Dixon JM
Breast Cancer Res Treat; 2011 Aug; 128(3):725-34. PubMed ID: 20941539
[TBL] [Abstract][Full Text] [Related]
11. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts.
Wu L; Birle DC; Tannock IF
Cancer Res; 2005 Apr; 65(7):2825-31. PubMed ID: 15805283
[TBL] [Abstract][Full Text] [Related]
12. Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer.
Garrido-Laguna I; Tan AC; Uson M; Angenendt M; Ma WW; Villaroel MC; Zhao M; Rajeshkumar NV; Jimeno A; Donehower R; Iacobuzio-Donahue C; Barrett M; Rudek MA; Rubio-Viqueira B; Laheru D; Hidalgo M
Br J Cancer; 2010 Aug; 103(5):649-55. PubMed ID: 20664591
[TBL] [Abstract][Full Text] [Related]
13. Determinants of rapamycin sensitivity in breast cancer cells.
Noh WC; Mondesire WH; Peng J; Jian W; Zhang H; Dong J; Mills GB; Hung MC; Meric-Bernstam F
Clin Cancer Res; 2004 Feb; 10(3):1013-23. PubMed ID: 14871980
[TBL] [Abstract][Full Text] [Related]
14. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.
Tabernero J; Rojo F; Calvo E; Burris H; Judson I; Hazell K; Martinelli E; Ramon y Cajal S; Jones S; Vidal L; Shand N; Macarulla T; Ramos FJ; Dimitrijevic S; Zoellner U; Tang P; Stumm M; Lane HA; Lebwohl D; Baselga J
J Clin Oncol; 2008 Apr; 26(10):1603-10. PubMed ID: 18332469
[TBL] [Abstract][Full Text] [Related]
15. Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma.
Cirstea D; Hideshima T; Rodig S; Santo L; Pozzi S; Vallet S; Ikeda H; Perrone G; Gorgun G; Patel K; Desai N; Sportelli P; Kapoor S; Vali S; Mukherjee S; Munshi NC; Anderson KC; Raje N
Mol Cancer Ther; 2010 Apr; 9(4):963-75. PubMed ID: 20371718
[TBL] [Abstract][Full Text] [Related]
16. Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer.
Buckner JC; Forouzesh B; Erlichman C; Hidalgo M; Boni JP; Dukart G; Berkenblit A; Rowinsky EK
Invest New Drugs; 2010 Jun; 28(3):334-42. PubMed ID: 19415181
[TBL] [Abstract][Full Text] [Related]
17. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors.
Wagner AJ; Malinowska-Kolodziej I; Morgan JA; Qin W; Fletcher CD; Vena N; Ligon AH; Antonescu CR; Ramaiya NH; Demetri GD; Kwiatkowski DJ; Maki RG
J Clin Oncol; 2010 Feb; 28(5):835-40. PubMed ID: 20048174
[TBL] [Abstract][Full Text] [Related]
18. Activation of the mammalian target of rapamycin signalling pathway in prostate cancer and its association with patient clinicopathological characteristics.
Dai B; Kong YY; Ye DW; Ma CG; Zhou X; Yao XD
BJU Int; 2009 Oct; 104(7):1009-16. PubMed ID: 19389013
[TBL] [Abstract][Full Text] [Related]
19. Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy.
Demetri GD; Chawla SP; Ray-Coquard I; Le Cesne A; Staddon AP; Milhem MM; Penel N; Riedel RF; Bui-Nguyen B; Cranmer LD; Reichardt P; Bompas E; Alcindor T; Rushing D; Song Y; Lee RM; Ebbinghaus S; Eid JE; Loewy JW; Haluska FG; Dodion PF; Blay JY
J Clin Oncol; 2013 Jul; 31(19):2485-92. PubMed ID: 23715582
[TBL] [Abstract][Full Text] [Related]
20. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.
Sun SY; Rosenberg LM; Wang X; Zhou Z; Yue P; Fu H; Khuri FR
Cancer Res; 2005 Aug; 65(16):7052-8. PubMed ID: 16103051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
